AIMS: Toll-like receptor 9 (TLR-9) is a cellular DNA receptor that has been linked previously to invasion in various cancers. The aim of this study was to investigate TLR-9 expression and its possible association with prognosis in oesophageal adenocarcinoma. METHODS AND RESULTS: Immunohistochemical TLR-9 expression was graded in clinical specimens (n = 76) of oesophageal adenocarcinoma. The TLR-9 immunostaining intensity was compared with tumour grade, stage and indicators of proliferation, apoptosis and tumour vascular supply. High TLR-9 expression correlated with advanced tumour stage, tumour unresectability, poor differentiation and high proliferation. Strong immunoreactivity of TLR-9 also indicated poor overall survival. CONCLUSIONS: High TLR-9 expression is associated with poor differentiation, a high proliferation rate and disseminated disease. Accordingly, increased TLR-9 expression may contribute to the growth and metastatic properties of oesophageal adenocarcinoma. 2011 Blackwell Publishing Limited.
AIMS: Toll-like receptor 9 (TLR-9) is a cellular DNA receptor that has been linked previously to invasion in various cancers. The aim of this study was to investigate TLR-9 expression and its possible association with prognosis in oesophageal adenocarcinoma. METHODS AND RESULTS: Immunohistochemical TLR-9 expression was graded in clinical specimens (n = 76) of oesophageal adenocarcinoma. The TLR-9 immunostaining intensity was compared with tumour grade, stage and indicators of proliferation, apoptosis and tumour vascular supply. High TLR-9 expression correlated with advanced tumour stage, tumour unresectability, poor differentiation and high proliferation. Strong immunoreactivity of TLR-9 also indicated poor overall survival. CONCLUSIONS: High TLR-9 expression is associated with poor differentiation, a high proliferation rate and disseminated disease. Accordingly, increased TLR-9 expression may contribute to the growth and metastatic properties of oesophageal adenocarcinoma. 2011 Blackwell Publishing Limited.
Authors: Didier Meseure; Sophie Vacher; Kinan Drak Alsibai; Martine Trassard; André Nicolas; Renaud Leclere; Florence Lerebours; Jean Marc Guinebretiere; Elisabetta Marangoni; Rosette Lidereau; Ivan Bieche Journal: Cancer Microenviron Date: 2016-07-09
Authors: Heikki Huhta; Olli Helminen; Joonas H Kauppila; Heikki Takala; Kalervo Metsikkö; Petri Lehenkari; Juha Saarnio; Tuomo Karttunen Journal: Virchows Arch Date: 2015-04-03 Impact factor: 4.064
Authors: Joni Leppänen; Olli Helminen; Heikki Huhta; Joonas H Kauppila; Joel Isohookana; Kirsi-Maria Haapasaari; Petri Lehenkari; Juha Saarnio; Tuomo J Karttunen Journal: Virchows Arch Date: 2017-02-12 Impact factor: 4.064
Authors: Johanna Tuomela; Jouko Sandholm; Mika Kaakinen; Ankita Patel; Joonas H Kauppila; Joanna Ilvesaro; Dongquan Chen; Kevin W Harris; David Graves; Katri S Selander Journal: Breast Cancer Res Treat Date: 2013-11-10 Impact factor: 4.872
Authors: Mikko Mella; Joonas H Kauppila; Peeter Karihtala; Petri Lehenkari; Arja Jukkola-Vuorinen; Ylermi Soini; Päivi Auvinen; Markku H Vaarala; Hanna Ronkainen; Saila Kauppila; Kirsi-Maria Haapasaari; Katri S Vuopala; Katri S Selander Journal: Oncoimmunology Date: 2015-05-22 Impact factor: 8.110
Authors: Olli Helminen; Heikki Huhta; Petri P Lehenkari; Juha Saarnio; Tuomo J Karttunen; Joonas H Kauppila Journal: Oncoimmunology Date: 2016-01-25 Impact factor: 8.110
Authors: Olli Helminen; Heikki Huhta; Heikki Takala; Petri P Lehenkari; Juha Saarnio; Joonas H Kauppila; Tuomo J Karttunen Journal: Virchows Arch Date: 2013-11-13 Impact factor: 4.064